Induction of pulmonary carcinogenesis in Wistar rats by a single dose of 9, 10 Dimethylbenz(a)anthracene (DMBA) and the chemopreventive role of Diclofenac

Experimental and Molecular Pathology

Volumn 88, Issue 3, 2010, Pages 394-400

  Thakur, Poonam ^a   Sanyal, S N ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Apoptosis; COX 2; Diclofenac; Inflammation

Indexed keywords

CYCLOOXYGENASE 2; DICLOFENAC; DIMETHYLBENZ[A]ANTHRACENE; 7,12 DIMETHYLBENZ[A]ANTHRACENE; ANTINEOPLASTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS2 PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; LUNG CANCER; LUNG CARCINOGENESIS; NONHUMAN; RAT; WISTAR RAT; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; ENZYMOLOGY; LUNG; LUNG ALVEOLUS MACROPHAGE; LUNG TUMOR; METABOLISM; PATHOLOGY;

ANIMALIA; RATTUS NORVEGICUS;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; APOPTOSIS; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DICLOFENAC; FEMALE; LUNG; LUNG NEOPLASMS; MACROPHAGES, ALVEOLAR; RATS; RATS, WISTAR;

EID: 77952563227     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2010.03.005     Document Type: Article

References (38)

1. Asgari M., et al. Nonsteroidal anti-inflammatory drug use in the prevention and treatment of squamous cell carcinoma. Dermatol. Surg. 2004, 30:1335-1342.
2. Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001, 357:539-545.
3. Bauers A.K., et al. High cyclooxygenase 1 (COX-1) and cyclooxygenase 2 (COX-2) contents in mouse lung tumors. Carcinogenesis 2000, 21(4):543-555.
4. Bradford M.M. A rapid and sensitive method for the quantitaion of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
5. Buters J., et al. CYP1B1 determines susceptibility to low doses of 7, 12-dimethylbenz[a]anthracene induced ovarian cancers in mice: correlation of CYP1B1-mediated DNA adducts with carcinogenicity. Carcinogenesis 2003, 24:327-334.
6. Castelao J.E., et al. Lung cancer and cyclooxygenase-2. Ann. Thorac. Surg. 2003, 76:1327-1335.
7. Chang H.C., Weng C.F. Cyclooxygenase-2 level and culture conditions influence NS398-induced apoptosis and caspase activation in lung cancer cells. Oncol. Res. 2001, 8:1321-1325.
8. Chen J.J., et al. Tumor-associated macrophages: the double-edged sword in cancer progression. J. Clin. Oncol. 2005, 23(5):953-964.
9. Cho M., et al. Diclofenac attenuates Wnt/b-catenin signaling in colon cancer cells by activation of NF-K{cyrillic}B. FEBS Lett. 2005, 579:4213-4218.
10. Cryer B., Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am. J. Med. 1998, 104(5):413-421.
11. Davilla D.R., et al. Human T cells are highly sensitive to suppression of mutagenesis by polycyclic aromatic hydrocarbons and this effect is differentially reversed by Α-naphthoflavone. Toxicol. Appl. Pharmacol. 1996, 139:333-341.
12. Gately S. The contribution of cyclooxygenase 2 to tumor angiogenesis. Cancer Metastasis Rev. 2000, 19:19-27.
13. Giuliano F., Warner T.D. Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs. Br. J. Pharmacol. 1999, 126:1824-1830.
14. Granberg A.L., et al. Cytochrome P50-dependent binding of 7, 12 dimethylbenz(a)anthracene (DMBA) and benzo(a)pyrene (B(a)P) in murine heart, lung, and liver endothelial cells. Arch. Toxicol. 2000, 74:593-601.
15. Gridelli C., et al. Selective cylooxygenase 2 inhibitors and non small cell lung cancer. Curr. Med. Chem. 2002, 9:1851-1858.
16. Grosch S., et al. Cyclooxygenase 2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J. Natl. Cancer Inst. 2006, 98(11):736-747.
17. Hilario M.O.E., et al. Nonsteroidal anti-inflammatory drugs: cyclooxyenase 2 inhibitors. J. Pediatr. 2006, 82(5):S206-S212.
18. Hofer M., et al. Hematopoeisis stimulating and antitumor effects of repeated administration of Diclofenac in mice with transplanted fibrosarcoma cells. Physiol. Res. 2002, 51:629-632.
19. Kaur J., Sanyal S.N. Association of PI3-kinase and Wnt signaling in non-steroidal anti-inflammatory drug-induced apoptosis in experimental colon cancer. Am. J. Biomed. Sci. 2009, 1(4):395-405.
20. Kleiner H.E., et al. Role of cytochrome P450 1a1 and 1b1 in the metabolic activation of 7, 12-dimethylbenz[a]-anthracene and the effects of naturally occurring furanocoumarins on skin tumor initiation. Chem. Res. Toxicol. 2002, 15:226-235.
21. Lee J.M., et al. Inflammation in lung carcinogenesis: new targets for lung cancer chemoprevention and treatment. Crit. Rev. Oncol. Hematol. 2008, 66:208-217.
22. Li N., et al. Inhibition of 7, 12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamsters by tea and curcumin. Carcinogenesis 2003, 23:1307-1313.
23. Lin M.T., et al. Cyclooxygenase-2 inducing mcl-1-dependent survival mechanism in human lung adenocarcinoma CL10 cells involvement of phosphatidylinositol 3-kinase/Akt pathway. J. Biol. Chem. 2001, 276:48997-49002.
24. Moody J.D., et al. Regio- and stereoselective metabolism of 7, 12-Dimethylbenz[a]anthracene by Mycobacterium vanbaalenii PYR-1. Appl. Environ. Microbiol. 2003, 69(7):3924-3931.
25. Pearse A.G.E. Histochemistry Theoretical and Applied 1968, Vol. 1. Churchill Livingstone, London, 660 pp. 3rd Edn.
26. Piazza G.A., et al. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res. 1997, 57:2452-2459.
27. Riedl K., et al. Multifaceted roles of cyclooxygenase-2 in lung cancer. Drug Resist. Updat. 2004, 7(3):169-184.
28. Ruegg C., et al. Nonsteroidal anti-inflammatory drugs and COX 2 inhibitors as anti cancer therapeutics: hypes, hopes and reality. Ann. Med. 2003, 35:476-487.
29. Saini R.K., Sanyal S.N. Pulmonary carcinogenesis in mice with a single intratracheal instillation of 9, 10-Dimethyl Benz(a)anthracene. Drug Chem. Toxicol. 2008, 31:459-471.
30. Sambrook J., et al. Molecular Cloning: a Laboratory Manual 1998, Cold Spring Harber Laboratory Press, Cold Spring Harber, New York, 192 pp. 2nd ed.
31. Schwartz L.M., Osborne B.A. Cell death. Meth. Cell Biol. 1995, 46:15-18.
32. Schweitzer A., Hasler-Nguyen N., Zijlstra J. Preferential uptake of the non steroid anti-inflammatory drug Diclofenac into inflamed tissues after a single oral dose in rats. BMC Pharmacol. 2009, 9(5).
33. Subbaramaiah K., Dannenberg A.J. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol. Sci. 2003, 24(2):96-102.
34. Suzuki J.S., et al. Metallothionein deficiency enhances skin carcinogenesis induced by 7, 12-dimethylbenz[a]anthracene and 12-O-tetradecanoylphorbol-13-acetate in metallothionein-null mice. Carcinogenesis 2003, 24:1123-1132.
35. Świercz R., Waa{ogonek}sowicz W., Majcherek W. Mesitylene (1, 3, 5-Trimethylbenzene) in the liver, lung, kidney, and blood and 3, 5-Dimethylbenzoic acid in the liver, lung, kidney and urine of rats after single and repeated inhalation exposure to mesitylene. Pol. J. Environ. Stud. 2006, 15(3):485-492.
36. Towbin H., et al. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA 1979, 76:4350-4354.
37. Wiese F.W., et al. Carcinogen substrate specificity of human COX-1 and COX-2. Carcinogenesis 2001, 22:5-10.
38. Zhu Y.M., et al. Effects of COX-2 inhibition on expression of vascular endothelial growth factor and interleukin-8 in lung cancer cells. BMC Cancer 2008, 8(218):1471-2407.